PureTech Health plc

PureTech reported no revenue or EPS in the call. On a consolidated basis, cash equivalents and short-term investments were $220.1 million at June 30, 2026, versus $277.3 million at year-end 2025; at the PureTech level the figure was approximately $220 million versus $277.1 million. Operating expenses were $55.9 million in the first six months of 2026, up from $49.8 million in the same period of 2025, reflecting higher R&D spend tied to Celea’s phase III preparation. Management said the operational runway remains at least through the end of 2028, excluding any inflows from monetization events and assuming full deployment of the additional $70 million reserved for potential future investment in Celea. Forwardly, PureTech expects significant reduction in overall OpEx moving forward and said clean cash burn, including overhead and innovation spend, is about $30 million to $40 million per year, down from roughly $90 million per year when later-stage programs were run internally.

Rob Lyne framed the period as proof that the refined strategy is working: advancing founded entities with external capital, retaining upside, and reducing capital intensity at the parent level. He highlighted Seaport’s IPO, Celea’s financing and phase III start, Gallop’s Fast Track designation, and continued Cobenfy economics as evidence of value creation across the portfolio. Tone-wise, he was constructive but disciplined, stressing runway management, selective capital deployment, and the ability to return capital to shareholders when appropriate.

Lyne emphasized balance-sheet strength and capital discipline, citing approximately $220 million in cash and short-term investments and runway at least through end-2028. He noted that OpEx rose to $55.9 million in the first half of 2026 from $49.8 million a year earlier because of Celea-related R&D, but said future expenses tied to deupirfenidone have shifted to Celea and should lower PureTech’s burn materially. He also said PureTech has reserved $70 million for potential future investment in Celea, and that clean cash burn is expected to be $30 million to $40 million annually versus roughly $90 million previously.

Analysts focused on Gallop’s STRIDE-MDS design, timing, biomarkers, and financing, plus how PureTech is thinking about capital allocation and the next wave of innovation programs. Management said the FDA accepted a mutation-agnostic approach and did not require biomarker selection, and that Gallop is targeting financing before starting STRIDE-MDS, with the trial expected to take under three years on conservative assumptions. On capital allocation, Lyne said PureTech will weigh cash runway, selective investment, and shareholder returns based on the relative cost of capital across equity, partnerships, and other structures.